Sandoz Champions Stability As It Returns To Growth In Q2
Investments In Biosimilars Will Spearhead Financial Goals
Sandoz enjoyed both top- and bottom-line growth in the second quarter, as the Novartis company rebounded from a challenging Q1 and explained how it would reach its financial targets in the longer term.
